A universal pharmacokinetic model was developed from pooled paediatric and adult data (40.6 postmenstrual weeks, 70.8 years, 3.1-152 kg). A three-compartment pharmacokinetic model with first-order elimination was superior to a two-compartment model to describe these pooled dexmedetomidine data. Population parameter estimates (population parameter variability %) were clearance (CL) 0.9 L/min/70 kg (36); intercompartmental clearances (Q2) […]
Archive | Uncategorized
Modeling of The Relationship Between Ustekinumab Exposure, Fecal Calprotectin and Endoscopic Outcomes in Patients with Crohn’s Disease
January 10, 2021
Authors Zhigang Wang (1), Bram Verstockt (2,3), João Sabino (2,3), Séverine Vermeire (2,3), Marc Ferrante (2,3), Paul Declerck (1), Erwin Dreesen (1,4)
Affiliations 1. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium 2. Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium 3. Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium 4. Department of Pharmacy, Uppsala University, Uppsala, Sweden
Presentation type Oral
Presenters Zhigang Wang
Background: Ustekinumab is approved for the treatment of patients with moderate-to-severe Crohn’s disease (CD) and ulcerative colitis. In the UNITI endoscopy sub-study, only 17.4% of patients on ustekinumab achieved endoscopic response and 10.9% of patients achieved endoscopic remission at week 44 (w44).1 Aims: We aimed to investigate if improved endoscopic outcomes could be achieved through dose optimization […]
External Evaluation of Vancomycin Models
January 10, 2021
Authors Guangda Ma (1), Eamon Duffy (1, 2), Jacqui Hannam (1), Nick Holford (1)
Affiliations (1) The University of Auckland, (2) Auckland District Health Board
Presentation type Poster
Presenters Guangda Ma
Introduction Current clinical evidence supports area under the concentration-time curve (AUC) rather than trough concentrations as a more rational target for vancomycin therapy (1). In mid-2019 practice at Auckland District Health Board Hospitals transitioned from trough concentration to AUC guided dosing supported by Bayesian forecasting using the GAVamycin model implemented in NextDose (www.nextdose.org). To support […]